

Supplemental Online Content

van der Loos MATC, Vlot MC, Klink DT, Hannema SE, den Heijer M, Wiepjes CM. Bone mineral density in transgender adolescents treated with puberty suppression and subsequent gender-affirming hormones. *JAMA Pediatr*. Published online October 30, 2023. doi:10.1001/jamapediatrics.2023.4588


eFigure. Flowchart of Study Participation

eTable 1. Characteristics of Individuals Not Included

eTable 2. Mean Change in BMD Z-Scores Between All Four Time Points, at Three Regions

This supplemental material has been provided by the authors to give readers additional information about their work.

eFigure. Flowchart of study participation



ACOG: Amsterdam Cohort of Gender Dysphoria, GnRHa: gonadotropin-releasing hormone agonist, GAH: gender-affirming hormones, AMAB: assigned male at birth, AFAB: assigned female at birth, DXA: dual-energy X-ray absorptiometry. ^a Persons either still in diagnostic phase or not diagnosed with gender dysphoria

eTable 1. Characteristics of individuals not included

	AMAB (n=40)		AFAB (n=28)	
At start of GnRHa				
Age (years)	13.8 (13.1;15.3)		15.9 (13.6;17.3)	
	<i>Male ref</i>	<i>Female ref</i>	<i>Male ref</i>	<i>Female ref</i>
Lumbar spine Z-score, mean (SD)	-0.20 (±1.02)	-1.03 (±0.91)	0.38 (±1.29)	-0.25 (±1.01)
Lumbar spine % Z-score < -2.0	7	11	0	0
Total hip Z-score, mean (SD)	-0.56 (±0.96)	-0.44 (±0.91)	-0.33 (±0.92)	0.06 (±0.90)
Total hip % Z-score < -2.0	4	0	0	0
Femoral neck Z-score, mean (SD)	-0.74 (±0.95)	-0.57 (±0.91)	-0.52 (±0.85)	-0.15 (±0.79)
Femoral neck % Z-score < -2.0	11	4	5	0
Age at start of GAH (years)	16.1 (16.0;16.9)		17.2 (16.3;17.9)	
Years of mono GnRHa	2.1 (1.5-2.8)		1.2 (0.6-2.6)	
Gonadectomy, n (%)	38 (95)		24 (86)	
Age at gonadectomy	19.1 (18.6;20.0)		19.2 (18.4; 19.9)	

Unless stated otherwise, data shown as median with interquartile range. AMAB: assigned male at birth; AFAB: assigned female at birth; GnRHa: gonadotropin-releasing hormone agonist; ref: reference; SD: standard deviation; GAH: gender-affirming hormones.

eTable 2. Mean change (95% CI) in BMD Z-scores between all four time points, at three regions of interest

	AMAB	AFAB
Lumbar spine		
Start GAH vs start GnRHa	-0.76 (-1.06;-0.46)	-1.10 (-1.30;-0.91)
Short-term FU vs start GAH	-0.09 (-0.44;0.26)	0.77 (0.55;0.98)
Long-term FU vs start GnRHa	-0.87 (-1.15;-0.59)	0.09 (-0.09;0.27)
Long-term FU vs start GAH	-0.11 (-0.40;0.18)	1.20 (1.01;1.38)
Total hip		
Start GAH vs start GnRHa	-0.57 (-0.77;-0.37)	-0.62 (-0.79;-0.46)
Short-term FU vs start GAH	0.42 (0.18;0.66)	0.63 (0.44;0.82)
Long-term FU vs start GnRHa	-0.12 (-0.31;0.07)	0.10 (-0.06;0.26)
Long-term FU vs start GAH	0.45 (0.26;0.65)	0.72 (0.56;0.89)
Femoral neck		
Start GAH vs start GnRHa	-0.52 (-0.70;-0.34)	-0.62 (-0.79;-0.45)
Short-term FU vs start GAH	0.54 (0.32;0.75)	0.59 (0.39;0.79)
Long-term FU vs start GnRHa	0.01 (-0.20;0.22)	-0.20 (-0.26;0.06)
Long-term FU vs start GAH	0.61 (0.43;0.78)	0.52 (0.35;0.69)

BMD: bone mineral density, AMAB: assigned male at birth; AFAB: assigned female at birth;
 GAH: gender-affirming hormones; GnRHa: gonadotropin-releasing hormone agonist; FU:
 follow-up